TY - JOUR
T1 - Paclitaxel as first- or second-line treatment for HIV-negative Kaposi’s sarcoma
T2 - a retrospective study of 58 patients
AU - Tourlaki, Athanasia
AU - Germiniasi, Francesca
AU - Rossi, Luisa Carlotta
AU - Veraldi, Stefano
AU - Brambilla, Lucia
PY - 2020
Y1 - 2020
N2 - Background: Paclitaxel has recently been approved for AIDS-related Kaposi’s sarcoma (KS) and there is much interest also in HIV-negative KS. Objective: To assess the safety and effectiveness of intravenous paclitaxel in the treatment of non-HIV-associated KS. Method: A retrospective database analysis of our departmental database in histologically proven, HIV-negative KS. Results: Fifty-eight patients treated with intravenous paclitaxel 100 mg weekly were identified. Among these patients, 11 patients underwent paclitaxel as first-line treatment, whereas 47 received paclitaxel after other types of systemic chemotherapy. Fifty-three (94.6%) patients achieved a partial or a complete remission after a mean of 13.5 infusions. Disease progression was observed in two patients and one patient had a stable disease. Thirty-one (58.5%) of 53 responding patients are still stable after a mean of 19.1 months of follow-up, while 22 (41.5%) patients relapsed after a mean of 14 months. Paclitaxel was repeated in relapsed patients obtaining PR/CR in all cases. Tolerance was good except for one patient who discontinued the treatment because of a severe allergic reaction. Conclusion: Paclitaxel is effective for the treatment of non-HIV-related KS, both as first- and as second-line treatment. It is well tolerated and can be repeated without loss of efficacy.
AB - Background: Paclitaxel has recently been approved for AIDS-related Kaposi’s sarcoma (KS) and there is much interest also in HIV-negative KS. Objective: To assess the safety and effectiveness of intravenous paclitaxel in the treatment of non-HIV-associated KS. Method: A retrospective database analysis of our departmental database in histologically proven, HIV-negative KS. Results: Fifty-eight patients treated with intravenous paclitaxel 100 mg weekly were identified. Among these patients, 11 patients underwent paclitaxel as first-line treatment, whereas 47 received paclitaxel after other types of systemic chemotherapy. Fifty-three (94.6%) patients achieved a partial or a complete remission after a mean of 13.5 infusions. Disease progression was observed in two patients and one patient had a stable disease. Thirty-one (58.5%) of 53 responding patients are still stable after a mean of 19.1 months of follow-up, while 22 (41.5%) patients relapsed after a mean of 14 months. Paclitaxel was repeated in relapsed patients obtaining PR/CR in all cases. Tolerance was good except for one patient who discontinued the treatment because of a severe allergic reaction. Conclusion: Paclitaxel is effective for the treatment of non-HIV-related KS, both as first- and as second-line treatment. It is well tolerated and can be repeated without loss of efficacy.
KW - chemotherapy
KW - intravenous paclitaxel
KW - Kaposi’s sarcoma
KW - taxanes
KW - treatment
UR - http://www.scopus.com/inward/record.url?scp=85064086280&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85064086280&partnerID=8YFLogxK
U2 - 10.1080/09546634.2019.1590520
DO - 10.1080/09546634.2019.1590520
M3 - Article
C2 - 30897011
AN - SCOPUS:85064086280
VL - 31
SP - 183
EP - 185
JO - Journal of Dermatological Treatment
JF - Journal of Dermatological Treatment
SN - 0954-6634
IS - 2
ER -